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Background: This study investigated the effects of Korean red ginseng (KRG) supplementation on metabolic parameters, 
inflammatory markers, and arterial stiffness in subjects with metabolic syndrome.
Methods: We performed a randomized, double-blind, placebo-controlled, single-center study in 60 subjects who were not 
taking drugs that could affect metabolic and vascular functions. Subjects were randomized into either a KRG (4.5 g/d) 
group or a placebo group for a 12-week study. We collected anthropometric measurements, blood for laboratory testing, 
and brachial-ankle pulse wave velocity (baPWV) at the initial (week 0) and final (week 12) visits.
Results: A total of 48 subjects successfully completed the study protocol. Oral administration of KRG did not significantly 
affect blood pressure, oxidative or inflammatory markers, or baPWV.
Conclusion: We found no evidence that KRG had an effect on blood pressure, lipid profile, oxidized low density lipoprotein, 
fasting blood glucose, or arterial stiffness in subjects with metabolic syndrome. These findings warrant subsequent 
longer-term prospective clinical investigations with a larger population.
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INTRODUCTION
Metabolic syndrome represents a cluster of cardiometabolic 
risk factors, including central obesity, elevated blood pressure, 
impaired glucose metabolism, and atherogenic dyslipidemia. 
The prevalence of metabolic syndrome is currently reaching 
epidemic proportions throughout the world. Subjects with 
metabolic syndrome are more susceptible to type 2 diabetes,1) 
cardiovascular disease (CVD),1) and some cancers,2) which are 
major leading causes of death, especially in developed countries.
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Panax ginseng has been used to promote general health and 
treat illness in traditional oriental medicine. Particularly, Korean 
red ginseng (KRG) has been reported to have various beneficial 
effects on vascular health, energy metabolism, pain-relief, and 
cancer prevention.3) Many animal studies have shown that KRG 
has potential benefits on cardiovascular disease and several 
metabolic parameters,4-8) but human studies have not provided 
consistent evidence yet.9-14) Moreover, although most human 
studies have been conducted in patients with individual diseases, 
such as hypertension, diabetes, and hyperlipidemia, little is known 
about the effects of KRG on cardiovascular risks in subjects with 
metabolic syndrome.
The aim of this double-blind, placebo-controlled, randomized 
study was to investigate the effects of KRG on cardiovascular risks 
in subjects with metabolic syndrome, including blood pressure, 
fasting plasma glucose, insulin sensitivity, lipid profile, oxidized 
low density lipoprotein (LDL) level, and arterial stiffness.
METHODS
1. Study Subjects
A single-center, double-blind, placebo-controlled, randomized 
clinical trial was designed. The study was approved by the 
institutional review board (IRB) of Gangnam Severance Hospital, 
Yonsei University College of Medicine in Seoul, Korea (IRB no. 
3-2009-0015). The study complied with the code of ethics of the 
World Medical Association (Declaration of Helsinki) with all 
subjects giving informed consent before participation.
Study subjects were older than 20 years of age, presented 
with metabolic syndrome, and were recruited by advertisement 
from August 2009 to December 2010. The modified National 
Cholesterol Education Program Adult Treatment Panel III was used 
for the definition of metabolic syndrome.15) Metabolic syndrome 
was defined by the presence of 3 or more of the following risk 
factors: 1) waist circumference ≥ 90 cm for men and ≥ 80 cm for 
women, 2) high triglyceride ≥ 150 mg/dL, 3) low high density 
lipoprotein (HDL) cholesterol < 40 mg/dL for men and < 50 
mg/dL for women, 4) elevated systolic blood pressure ≥ 130 mm 
Hg or elevated diastolic blood pressure ≥ 85 mm Hg, and 5) high 
fasting plasma glucose ≥ 100 mg/dL based on the revised American 
Diabetes Association criteria.16) Subjects were excluded if they were 
taking drugs that could affect metabolic and vascular functions, 
including blood pressure-lowering drugs, anti-diabetic drugs, and 
lipid-lowering drugs, had uncontrolled hypertension (systolic 
blood pressure ≥ 160 mm Hg or diastolic blood pressure ≥ 100 
mm Hg), fasting blood sugar ≥ 126 mg/dL, hyperlipidemia 
(triglycerides ≥ 400 mg/dL or total cholesterol ≥ 250 mg/dL), 
or a history of cardiovascular disease. After the initial screening 
visit, subjects were randomly assigned in a double-blind fashion 
to receive either 1.5 g of KRG (KRG powder capsule; Korea 
Ginseng Co., Seoul, Korea) or identical-appearing placebo with 
ginseng flavor three times a day for 12 weeks. Randomization 
was done according to computer-generated random number 
sequence. KRG was prepared from roots of a 6-year-old fresh 
Panax ginseng C.A. Meyer, which were harvested in Korea. Red 
ginseng was made by steaming fresh ginseng at 90oC to 100oC for 
3 hours and then drying at 50oC to 80oC. A voucher specimen 
was deposited at the Korea Ginseng Corporation. KRG was 
analyzed by high-performance liquid chromatography. KRG 
contained major ginsenoside-Rg1: 2.89%, Re: 2.16%, Rf: 0.93%, 
Rh1: 0.13%, Rg2: 0.58%, Rb1: 5.16%, Rc: 2.22%, Rb2: 1.82%, 
Rd: 0.47%, Rg3: 0.22%, and other minor ginsenosides.
2. Measurements
We collected anthropometric measurements, blood for 
laboratory testing, and brachial-ankle pulse wave velocity (baPWV) 
at the initial (week 0) and final (week 12) visits (Figure 1). Past 
medical history, health-related behaviors (smoking, alcohol 
intake, and regular exercise), and anthropometric measurements 
were obtained through a structured history review and a physical 
examination. Body weight and height were measured while the 
subject was wearing light indoor clothing without shoes and were 
rounded to the nearest 0.1 kg and 0.1 cm, respectively. Body mass 
index was calculated as the ratio of weight (kg)/height (m2). 
Blood pressure was measured in the right arm using a standard 
mercury sphygmomanometer (Baumanometer; WA Baum 
Co., Copiague, NY, USA). After a 12-hour overnight fast, blood 
samples were obtained from the antecubital veins. Specimens 
were centrifuged, and the serum was immediately frozen at 
-80oC. Leukocyte counts were quantified by an automated blood 
cell counter (ADVIA 120; Bayer, Tarrytown, NY, USA). Serum 
levels of blood glucose, insulin, high-sensitivity C-reactive protein 
(CRP), total cholesterol, HDL-cholesterol, and triglyceride 
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were assayed enzymatically (Bayer) using an ADVIA 1650 auto-
analyzer (Bayer). Insulin resistance was estimated using the 
homeostatic model assessment of insulin resistance (HOMA-IR) 
with the following equation: HOMA-IR = (fasting insulin [μIU/
mL] × fasting plasma glucose [mg/dL]/405). Oxidized LDL-
cholesterol was measured using an electrochemiluminescence 
immunoassay with the Mercodia Oxidized LDL Competitive 
ELISA test (Mercodia, Uppsala, Sweden), a solid-phase enzyme 
immunoassay modified from the original method of Holvoet et 
al.17) During incubation, oxidized LDL in the sample competes 
with a fixed amount of oxidized LDL bound to the microtiter 
wells for binding of biotin-labeled specific antibodies (mAb-4E6).
Arterial stiffness was measured via baPWV using a volume-
plethysmographic apparatus (PWV/ABI; Colin Co., Komaki, 
Japan). The coefficients of variation were 8.4% for interobserver 
reproducibility and 10.0% for intraobserver reproducibility.
3. Sample Size Estimation
The intended sample of 60 recruited subjects provided a 
power of approximately 80%, assuming a significance level 
< 0.05, to detect a 9.5 mm Hg placebo-adjusted treatment effect 
in systolic blood pressure (change from baseline to week 12) 
with a standard deviation of 11.5 mm Hg. The drop-out rate 
was expected to be less than 20%, based on the documented 
good tolerability of nutraceutical combination. The formula for 
the sample size was as follows: n = 2(zα/2 + zβ)
2 / {(μ0 - μ1) / 
σ}2; α = 0.05, β = 0.20, two population means (μ0 and μ1), σ2 = 
common variance.
4. Statistical Analysis
Data are presented as mean ± SD. The primary outcome 
(blood pressure and arterial stiffness) and the secondary outcome 
(metabolic and inflammatory markers) were used to compare 
the KRG group to the placebo group. The Wilcoxon signed-
rank test was used to calculate the significances of the differences 
from baseline in each group. The effects of treatment relative to 
the control levels were analyzed by comparing the changes from 
baseline between the two treatment arms using Wilcoxon rank-
sum test. All analyses were conducted using SAS ver. 9.1 (SAS 
Inc., Cary, NC, USA). All statistical tests were two-sided, and a P 
< 0.05 was considered significant.
Figure 1. Flowchart of the study 
design and subject participation. 
KRG: Korean red ginseng, baPWV: 
brachial-ankle pulse wave velocity.
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RESULTS
The study criteria were met by 60 subjects who were 
randomized for participation. We defined good compliance as 
taking more than 80% of the pills given to the participants. Of 
these, 12 subjects withdrew (11 due to noncompliance and 1 due 
to time conflicts) and 48 subjects completed the study (KRG 
group, n = 23; placebo group, n = 25) (Figure 1). According to the 
self-reported questionnaire, one subject reported gastrointestinal 
disturbance after placebo administration, whereas there were no 
reported adverse reactions to KRG administration.
Baseline characteristics of all subjects are presented in Table 
1. The following parameters were similar in both the KRG and 
placebo group: age, waist circumference, systolic blood pressure, 
diastolic blood pressure, fasting plasma glucose, total cholesterol, 
HDL-cholesterol, triglyceride, insulin, oxidized LDL, CRP, 
leukocyte count, and baPWV. Table 2 summarizes the inter- 
and intra-group differences in metabolic parameters, arterial 
stiffness, and inflammatory markers. Mean waist circumference 
and systolic blood pressure decreased significantly in the KRG 
group (P = 0.015 and P = 0.038, respectively) and mean HDL-
cholesterol increased in the KRG group (P = 0.019). Mean 
systolic blood pressure and diastolic blood pressure decreased 
in the placebo group (P < 0.001 and P < 0.001, respectively). 
However, the extent of change in waist circumference, blood 
pressure, and HDL-cholesterol between the KRG and placebo 
groups was not significantly different. Oral administration of 
KRG did not significantly affect blood pressure; inflammatory 
markers, including oxidized LDL, CRP, and leukocyte count; or 
baPWV.
Table 1. Clinical characteristics of the subjects at baseline.
Ginseng group (n = 29) Placebo group (n = 31) P-value*
Female 9 (31.0) 12 (38.7) 0.533
Age (yr)    43.1 ± 10.6  46.2 ± 11.0 0.263
Waist circumference (cm) 95.7 ± 9.0 91.8 ± 7.7 0.069
Systolic blood pressure (mm Hg) 134.4 ± 11.2 131.6 ± 10.8 0.316
Diastolic blood pressure (mm Hg) 85.7 ± 8.8 85.7 ± 8.3 0.971
Total cholesterol (mg/dL) 193.2 ± 41.6 192.0 ± 26.8 0.898
High density lipoprotein cholesterol (mg/dL)  44.1 ± 11.6 42.3 ± 8.4 0.472
Triglyceride (mg/dL) 163.9 ± 94.4  207.5 ± 210.5 0.301
Oxidized low density lipoprotein (μIU/mL)  88.8 ± 40.2  81.5 ± 32.3 0.445
Fasting plasma glucose (mg/dL) 106.7 ± 18.8 116.4 ± 65.9 0.437
Insulin (μIU/mL) 11.1 ± 8.7   9.9 ± 10.3 0.626
Homeostasis model assessment of insulin resistance  3.1 ± 2.9  3.1 ± 4.2 0.989
C-reactive protein (mg/L)  2.0 ± 2.0  2.0 ± 2.4 0.941
White blood cell count (103 cells/μL)  7.05 ± 2.22  6.28 ± 1.32 0.115
Brachial-ankle pulse wave velocity (cm/s) 1,288 ± 150 1,323 ± 162 0.392
Current smoker 11 (37.9)  8 (25.8) 0.122
Alcohol ingestion† 12 (41.4) 10 (32.3) 0.463
Physical activity‡ 13 (44.8)  8 (25.8) 0.122
Values are presented as mean ± SD or number (%).
*P-values were calculated with t-test or chi-square test. †Alcohol drinking ≥ 140 g/wk. ‡Regular exercise ≥ twice/wk.
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DISCUSSION
In this double-blind, randomized, and placebo-controlled 
study, there was no significant improvement in metabolic 
parameters, oxidative or inflammatory markers, or baPWV after 
oral administration of KRG compared to the placebo group.
Central obesity is a core characteristic of metabolic syndrome. 
Increased visceral adipose tissues are accompanied by chronic low 
grade inflammation and insulin resistance, which explains various 
features of metabolic syndrome. Adipose tissue is now accepted 
as an endocrine organ that secretes a variety of adipokines 
and cytokines. Thus, metabolic syndrome is implicated by an 
increased production of proinflammatory cytokines, such as 
interleukin-6 and tumor necrosis factor-α.18,19) These cytokines 
play a key role in regulating the vessel wall tone by affecting the 
release of nitric oxide and endothelin-1 in the subendothelial 
space.20,21) This cascade may cause endothelial dysfunction 
and alter arterial elastic properties, leading to increased blood 
pressure and structural stiffness. KRG has several constituents 
with curable properties, of which ginsenosides have been noticed 
to be a major pharmacologic component. In animal studies and 
an in vitro study using human umbilical vein endothelial cell,22-24) 
ginsenosides relax blood vessels and improve blood flow through 
nitric oxide release by activating endothelial nitric oxide synthase. 
Human clinical trials have demonstrated that KRG has favorable 
effects on blood pressure, and the study included a range of 
subjects, from those in good health to patients with congestive 
heart failure, but the majority of patients did not demonstrate a 
significant change in response to KRG administration.25) Han 
et al.10) reported that red ginseng significantly decreased systolic 
blood pressure in essential hypertension patients without anti-
hypertensive medication. Some studies have reported that 
ginseng slightly increased blood pressure,9,26) but the study was 
conducted in healthy subjects. Therefore, there was a possibility 
that KRG’s effects vary according to baseline blood pressure. 
We excluded subjects who were currently taking drugs that 
could modify metabolic and vascular function parameters, and 
patients in need of medical treatment. This may have resulted in 
a study population with relatively early metabolic syndrome that 
Table 2. Changes in the laboratory values after the administration of the ginseng or placebo for 12 weeks.
Ginseng group (n = 23) Placebo group (n = 25)
P-value‡
Before Δ* P-value* Before Δ P-value†
Waist circumference (cm) 94.7 ± 8.2 -2.4 ± 4.3 0.015 90.5 ± 6.8 -0.8 ± 4.7 0.268 0.226
Systolic blood pressure (mm Hg) 134.5 ± 12.0 -7.0 ± 15.0 0.038 129.3 ± 10.5 -6.8 ± 7.6 <0.001 0.917
Diastolic blood pressure (mm Hg) 85.6 ± 9.7 -3.5 ± 8.5 0.094 83.8 ± 8.0 -4.2 ± 5.5 <0.001 0.717
Total cholesterol (mg/dL) 189.9 ± 39.4  4.2 ± 16.3 0.283 191.2 ± 26.6 1.2 ± 24.3 0.771 0.342
HDL cholesterol (mg/dL)  43.3 ± 10.1 3.0 ± 8.2 0.019 41.9 ± 8.3 0.6 ± 6.4 0.374 0.268
Triglyceride (mg/dL) 163.6 ± 99.5  5.1 ± 75.0 0.694  204.6 ± 227.9 -28.4 ± 136.3 0.972 0.764
Oxidized LDL (μIU/mL)  79.5 ± 35.9 -5.1 ± 40.9 0.621  83.0 ± 35.2 2.5 ± 51.7 0.836 0.687
Fasting plasma glucose (mg/dL) 107.0 ± 19.9  3.4 ± 17.2 0.941 105.5 ± 12.5 0.9 ± 11.0 0.734 0.942
Insulin (μIU/mL) 10.9 ± 8.3  1.2 ± 18.7 0.153  10.4 ± 11.3 -2.7 ± 9.3 0.123 0.679
HOMA-IR  3.1 ± 3.0 0.9 ± 7.7 0.365  2.8 ± 3.4 -0.7 ± 2.9 0.322 0.772
C-reactive protein (mg/L)  2.1 ± 2.1 -0.4 ± 2.1 0.219  2.0 ± 2.5 -0.1 ± 2.9 0.671 0.515
WBC count (103 cells/μL)  7.0 ± 2.1 -0.4 ± 1.6 0.441  6.4 ± 1.4 0.1 ± 1.4 0.896 0.451
baPWV (cm/s) 1,272 ± 155 -11.9 ± 113.8 0.477 1,289 ± 153 27.1 ± 122.8 0.306 0.259
HDL: high density lipoprotein, LDL: low density lipoprotein, HOMA-IR: homeostasis model assessment for insulin resistance, WBC: white 
blood cell, baPWV: brachial-ankle pulse wave velocity.
*Δ: change after 12 weeks. †P-value was calculated by Wilcoxon signed-rank test for within-treatment differences. ‡P-value was calculated 
by Wilcoxon rank-sum test for between-treatment differences.
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attenuated the favorable effects of KRG.
KRG has also been reported to improve insulin resistance and 
have anti-hyperlipidemic effects.7,11,27) Furthermore, some studies 
have indicated that KRG might reduce weight gain.28,29) Although 
the reason for favorable energy metabolism of KRG is unclear, 
it may be explained by activation of adenosine monophosphate-
activated protein kinase29) and reductions in food intake or 
appetite.30) However, firm evidence is still lacking in clinical 
trials.25)
The lack of beneficial effects for KRG in this study has 
several possible explanations. First, we could not fully control 
participants’ lifestyle such as exercise and diet. Although all 
participants were instructed to exercise on a regular basis and 
mildly reduce their calorie intake, each individual’s compliance 
may have been different. Second, the relationship between KRG 
dosage and its effect on CVD risks was not evaluated. Further 
research is warranted to clarify the influence of a dose-effect 
relationship to determine the optimum dosage in subjects with 
metabolic syndrome. Third, the ginsenoside Rg3 has been known 
to improve insulin sensitivity,31) but the 0.22% of Rg3 used in 
this study may be too low to be expected to have any beneficial 
effects on metabolic parameters. Lastly, gender differences were 
not considered. Further investigation is warranted to better 
understand gender differences in the cardiovascular effects of 
KRG in subjects with metabolic syndrome.
In conclusion, we found no evidence that KRG had an effect 
on blood pressure, lipid profile, oxidized LDL, fasting blood 
glucose, or arterial stiffness in subjects with metabolic syndrome. 
These findings warrant further longer-term prospective clinical 
investigations with a larger population.
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